Moderna’s Covid-19 vaccine shows significant effect in early human trial
The company has reported positive interim clinical data of mRNA-1273 from the phase 1 study by the National Institute of Allergy and Infectious Diseases (NIAID), part of the
Enhertu, a HER2-directed antibody drug conjugate (ADC), is being studied under a comprehensive development programme to assess the efficacy and safety of the monotherapy across multiple HER2-driven cancers